Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Truist Financial Sticks to Their Buy Rating for Regeneron (REGN)

Tipranks - Tipranks - Fri Apr 24, 6:50AM CDT

In a report released today, Gregory Renza from Truist Financial maintained a Buy rating on Regeneron, with a price target of $801.00.

Claim 30% Off TipRanks

Renza covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Viridian Therapeutics, and Regeneron. According to TipRanks, Renza has an average return of 17.8% and a 47.17% success rate on recommended stocks.

In addition to Truist Financial, Regeneron also received a Buy from TD Cowen’s Tyler Van Buren in a report issued today. However, on the same day, Scotiabank maintained a Hold rating on Regeneron (NASDAQ: REGN).

See Insiders’ Hot Stocks on TipRanks >>

Based on Regeneron’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $3.88 billion and a net profit of $844.6 million. In comparison, last year the company earned a revenue of $3.79 billion and had a net profit of $917.7 million

Read More on REGN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).